Published in Gastroenterologie clinique et biologique
The aim of this survey was to study the requests written for hepatitis B virus (HBV) serology tests to ascertain their compliance with French prescription guidelines; additional costs incurred by inappropriate requests were also determined, as was the appropriateness of the physicians' interpretation of the test results. This was a cross-sectional ...
Published in Gastroenterologie clinique et biologique
Although lacking in statistical power, these results confirm that patients with sporadic duodenal adenoma are at high risk of colonic adenoma and advanced neoplasia, warranting systematic colonoscopy.
Published in Gastroenterologie clinique et biologique
Esophageal motor disorders are frequently seen in scleroderma, especially in cases with clinical symptoms, but are not associated with a specific form of the disease.
Published in Gastroenterologie clinique et biologique
To assess the trends in incidence, therapeutic modalities and survival of pancreatic cancer between 1978 and 2002 in a well-defined population, as recorded in the Calvados digestive cancer registry database. All patients living in Calvados with a diagnosis of pancreatic cancer were registered. Clinical data and treatment modalities were prospective...
Published in Gastroenterologie clinique et biologique
During the 20th century, gastro-esophageal reflux moved from the status of a rare and severe disease to that of a frequent disease occurring mostly, in the absence of any significant lesions. Proton pump inhibitors (PPIs) are the mainstay of its therapy and are prescribed mainly in an empirical way. Extradigestive manifestations require more accura...
Published in Gastroenterologie clinique et biologique
According to these findings, the benefit of interferon treatment on fibrosis progression is clinically significant in patients with advanced fibrosis by the reduction of fibrosis progression to cirrhosis. Pegylated interferon now needs to be compared, in terms of benefit-risk factors, with the new generation of HBV treatments (such as entecavir and...
Published in Gastroenterologie clinique et biologique
Nucleoside or nucleotide analogs (NUCs) are a major step forward in the treatment of hepatitis B virus (HBV) infection. Apart from their proven antiviral efficacy, these drugs have proved able to significantly improve liver fibrosis as short-term treatment. Using different definitions of fibrosis regression, after 1 year of treatment, improvement i...
Published in Gastroenterologie clinique et biologique
In patients with portal hypertension due to cirrhosis, the mechanisms responsible for circulatory modifications are well-known. An elevation in intrahepatic vascular resistance related to a hepatic endothelin hyperproduction and an arterial nitric oxide (NO) hyperproduction. The presence and the degree of portal hypertension might be determined by ...
Published in Gastroenterologie clinique et biologique
Since the first description of nonalcoholic steatohepatitis (NASH) in 1980, much progress has been made towards its individualisation as a liver disease with potentially serious consequences. The identification of insulin resistance as a major determinant of steatogenesis and possibly of liver disease progression helped to identify a cause of this ...
Published in Gastroenterologie clinique et biologique
Hepatocellular carcinoma is the main type of primary liver cancer. It is a major complication of chronic liver diseases, mainly cirrhosis. High increase in incidence and mortality has been observed in industrialized countries for about 30 years, as well as major improvement in the understanding of carcinogenesis and diagnostic and therapeutic manag...
